Putin backs off for now...
Putin backs off for now... The S&P 500 hits an all-time high... Dan Ferris on Berkshire Hathaway... Klarman is worried about the markets... Big wins on NovaGold and Lorillard... Uranium hits a new high... Jeff Clark is bullish on gold...
There's no shortage of headlines on the topic, so we won't spend much time talking about it...
In short, Russia is backing down for now. Russian troops on the Ukrainian border were ordered to return to base. Russian President Vladimir Putin told the press, "As for the use of military force, there is no need for it... But we have that option." He also reiterated his support for "the legitimate [Ukrainian] President" Viktor Yanukovych, who was forced out of office.
We doubt this conflict is close to over... But Mr. Market is happy today... The S&P 500 hit a record high.
Yesterday, we noted investment legend Warren Buffett was buying stocks on market weakness. (He ignores macro factors, choosing to focus solely on business fundamentals.) Buffett stole headlines yesterday after his holding company, Berkshire Hathaway, announced record earnings. You can read yesterday's discussion of Buffett and Berkshire here.
We asked Dan Ferris, who holds Berkshire Hathaway shares in his Extreme Value portfolio, for his thoughts on the company's announcement...
|
Another billionaire guru, Baupost Group founder Seth Klarman, just released his most recent shareholder letter. Baupost Group is one of the world's largest hedge funds, with around $25 billion under management. And in 2013, Klarman held a record high 50% of his fund in cash (up from 36% in 2012). He also announced he would return $4 billion to investors because he didn't want the fund to grow too quickly and dilute performance. (In other words, he doesn't see enough opportunity in the markets today.)
Klarman has long been critical of the Federal Reserve's market manipulation. And while he acknowledges we're in the midst of a bull market, he's still skeptical. Value-investing website ValueWalk received a copy of Klarman's letter. From ValueWalk...
|
Klarman shares our views... We know how the Fed's market-boosting efforts will eventually end. But for now, the trend is up... We remain cautiously optimistic.
Gold soared nearly 2.5% yesterday on fears surrounding the situation in Ukraine. (It's down today as fears subsided.) The precious metal hit a four-month high of $1,354 an ounce yesterday. Gold stocks, as measured by the Market Vectors Gold Miners Fund (GDX), were up 1.6%.
Stansberry's Investment Advisory recommendation NovaGold (NG) was up 1.9% yesterday. Porter and his research team recommended the gold miner in the November issue...
|
Another Porter recommendation, tobacco company Lorillard (LO), jumped more than 9% yesterday on rumors from the Financial Times that competitor Reynolds American may make a bid for the company. Reynolds has hired investment bank Lazar to explore the deal, which would value Lorillard at more than $20 billion, according to the Financial Times.
Neither company commented on the news. Lorillard shares are up another 1.5% as of midday trading today. As of yesterday's close, Porter's Stansberry Alpha subscribers were up 61% on margin... in just five days.
DailyWealth Trader editor Amber Lee Mason noted uranium hit a two-year high in yesterday's Growth Stock Wire...
|
S&A Resource Report subscribers are sitting on big gains from uranium giant Cameco. Shares are up 36% since editor Matt Badiali recommended them in December 2012.
While shares of gold and silver stocks have popped higher over the last couple months, one gold stock has been left behind. And Jeff thinks shares are about to jump higher... He believes the trade he just recommended to subscribers could return 135% over the next three months as the stock recovers.
As Jeff explained this morning, despite its recent rally, he sees more upside for gold stocks...
|
The company Jeff just recommended a trade on is lagging other miners because its production and margins are on the decline. But as gold prices move higher, this company's margins and profits will improve. And shares are so beaten down, any good news could send the stock soaring higher.
New 52-week highs (as of 3/3/14): Brazil Resources (BRI.V), Cameco (CCJ), CF Industries (CF), Denison Mines (DNN), Energy Transfer Equity (ETE), GigaMedia (GIGM), Lorillard (LO), and Skyworks Solutions (SWKS).
One subscriber is enjoying his profits on Lorillard. Is your portfolio performing well with stocks at record highs? Let us know at feedback@stansberryresearch.com.
"Okay, I was just about to let Porter have it and jump on the 'what have you done for me lately' bandwagon and boom! RJ Reynolds is milling around a buy out of Lorillard! What, did the RJ Reynolds hierarcy read Porter and companies call on Lorillard also? Nice! Buy the way, Porter has had some great energy plays in the last year also.
"Now, about this Russia, Ukrainian thing. Sadly I'm old enough to have seen this time and time again. Now that Putin, an ex-KGB guy, come on; this was unexpected? He would like nothing more than to assemble the old USSR bear. Get real and move on, he's already in there and will be extremely difficult to remove. I'm just glad this is taking his attention and diverting it from other areas of the world. Guess I better get out the old Beatles, White Album and listen to 'Back in the USSR.' Sounds like a plan! Nice call Porter!" – Paid-up subscriber Steve
Regards,
Sean Goldsmith
Miami Beach, Florida
March 4, 2014
Five medical breakthroughs that will change your life...
In today's Digest Premium, we share part of biotech expert Dave Lashmet's presentation from last weekend's Stansberry Society event.
Dave discussed five medical breakthroughs that will help you beat heart disease, cancer, stroke, and other potentially lethal afflictions. And he shared a few companies that are set to benefit from these long-term trends...
To subscribe to Digest Premium and receive a free hardback copy of Jim Rogers' latest book, click here.
Five medical breakthroughs that will change your life...
Stansberry's Investment Advisory research analyst David Lashmet gave one of the best presentations at our first-ever Stansberry Society event in Miami. Dave is an expert in early-stage technologies (particularly in the biotechnology space).
His presentation was titled "65 is the New 45: Five Medical Breakthroughs by 2015." In it, he outlined five technologies that will help decrease heart attacks, increase cancer-survival rates, restore liver function, improve life for diabetics, and clear out Alzheimer's plaque.
The No. 1 killer in the U.S. is heart disease (like heart attacks and strokes). Heart disease is tied to bad cholesterol. And right now, pharmaceutical companies are working on new ways to reduce its risks.
Several firms have developed drugs that are designed to cut cholesterols without taking statins (a specific type of cholesterol-reducing drug). Statins can reduce your cholesterols by 70%... The PCSK9, self-injectable drugs will reduce the risk of heart attack up to 75%... And the pivotal trials are this year. Dave expects we'll see these drugs on the market within two years.
Three companies are producing these drugs: Amgen, Sanofi's Regeneron, and Pfizer. Dave says Amgen is in the lead... It reported results on 3,957 patients last month in final-phase clinical trials. And it's increasing that sample size. It's way ahead of its competitors in terms of testing.
Here is the slide from Dave's presentation:
– Sean Goldsmith
Editor's note: We're hosting our second Stansberry Society meeting in Dallas on May 31... It's focused on natural resources. And we've secured one of the world's biggest names in natural resources to speak at the conference: billionaire oilman T. Boone Pickens.
He's just one of the major speakers we've secured... We'll also have Sprott Resources investing legend Rick Rule and Texas wildcatter Cactus Schroeder, among others.
We're offering 200 "early bird" tickets to this event for only $299. We've already sold many of them. If you're interested, we'd urge you to act quickly. You can learn more here.
Five medical breakthroughs that will change your life...
In today's Digest Premium, we share part of biotech expert Dave Lashmet's presentation from last weekend's Stansberry Society event.
Dave discussed five medical breakthroughs that will help you beat heart disease, cancer, stroke, and other potentially lethal afflictions. And he shared a few companies that are set to benefit from these long-term trends...
To continue reading, scroll down or click here.
Stansberry & Associates Top 10 Open Recommendations
(Top 10 highest-returning open positions across all S&A portfolios)
As of 03/04/2014
| Stock | Symbol | Buy Date | Return | Publication | Editor |
| Prestige Brands | PBH | 05/13/09 | 369.8% | Extreme Value | Ferris |
| Constellation Brands | STZ | 06/02/11 | 282.1% | Extreme Value | Ferris |
| Enterprise | EPD | 10/15/08 | 266.8% | The 12% Letter | Dyson |
| Ultra Health Care | RXL | 03/17/11 | 245.8% | True Wealth | Sjuggerud |
| Ultra Nasdaq Biotech | BIB | 12/05/12 | 241.9% | True Wealth Sys | Sjuggerud |
| Fluidigm | FLDM | 08/04/11 | 215.2% | Phase 1 | Curzio |
| Ultra Health Care | RXL | 01/04/12 | 202.1% | True Wealth Sys | Sjuggerud |
| Fission Uranium | FCU-V | 04/30/13 | 189.6% | Phase 1 | Curzio |
| Hershey | HSY | 12/06/07 | 182.3% | SIA | Stansberry |
| Altria | MO | 11/19/08 | 170.7% | The 12% Letter | Dyson |
Please note: Securities appearing in the Top 10 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the model portfolio of any S&A publication. The buy date reflects when the editor recommended the investment in the listed publication, and the return shows its performance since that date. To learn if a security is still a recommended buy today, you must be a subscriber to that publication and refer to the most recent portfolio.
| Top 10 Totals |
| 2 | Extreme Value | Ferris |
| 2 | The 12% Letter | Dyson |
| 1 | True Wealth | Sjuggerud |
| 2 | True Wealth Sys | Sjuggerud |
| 2 | Phase 1 | Curzio |
| 1 | SIA | Stansberry |
Stansberry & Associates Hall of Fame
(Top 10 all-time, highest-returning closed positions across all S&A portfolios)
| Investment | Sym | Holding Period | Gain | Publication | Editor |
| Seabridge Gold | SA | 4 years, 73 days | 995% | Sjug Conf. | Sjuggerud |
| Rite Aid 8.5% bond | 4 years, 356 days | 773% | True Income | Williams | |
| ATAC Resources | ATC | 313 days | 597% | Phase 1 | Badiali |
| JDS Uniphase | JDSU | 1 year, 266 days | 592% | SIA | Stansberry |
| Silver Wheaton | SLW | 1 year, 185 days | 345% | Resource Rpt | Badiali |
| Jinshan Gold Mines | JIN | 290 days | 339% | Resource Rpt | Badiali |
| Medis Tech | MDTL | 4 years, 110 days | 333% | Diligence | Ferris |
| ID Biomedical | IDBE | 5 years, 38 days | 331% | Diligence | Lashmet |
| Northern Dynasty | NAK | 1 year, 343 days | 322% | Resource Rpt | Badiali |
| Texas Instr. | TXN | 270 days | 301% | SIA | Stansberry |